Methods and compositions for treating diabetes
Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.
1. An oral pharmaceutical composition, comprising an oil-based liquid formulation, said oil-based liquid formulation comprising an insulin, exenatide, a protease inhibitor, and a chelator of divalent cations, wherein said oil-based liquid formulation is surrounded by a coating that resists degradation in the stomach,
wherein said insulin is present in an amount of between 6-14 milligrams inclusive and said exenatide is present in an amount of between 100-500 micrograms inclusive for an adult patient or a corresponding amount per body weight for a pediatric patient, and
wherein administration of the composition to a subject prior to caloric ingestion lengthens the time that the subject's blood sugar is lowered, after caloric ingestion, to a level that is lower than the level that results if the subject was administered a control composition that is the same except that it lacks the insulin, the exenatide, or both.
2. An oral pharmaceutical composition, comprising a combination of i) a first oil-based liquid formulation, said first oil-based liquid formulation comprising an insulin, a protease inhibitor, and a chelator of divalent cations; and ii) a second oil-based liquid formulation, said second oil-based liquid formulation comprising exenatide, a protease inhibitor, and a chelator of divalent cations, wherein each of said first oil-based liquid formulation and said second oil-based liquid formulation is surrounded by a coating that resists degradation in the stomach,
wherein said insulin is present in an amount of between 6-14 milligrams inclusive and said exenatide is present in an amount of between 100-500 micrograms inclusive for an adult patient or a corresponding amount per body weight for a pediatric patient, and
wherein administration of the composition to a subject prior to caloric ingestion lengthens the time that the subject's blood sugar is lowered, after caloric ingestion, to a level that is lower than the level that results if the subject was administered a control composition that is the same except that it lacks the insulin, the exenatide, or both.
3. The oral pharmaceutical composition of claim 1 , wherein said oil-based liquid formulation, further comprises a component provided as a mixture of (a) a monoacylglycerol, a diacylglycerol, a triacylglycerol, or a mixture thereof; and (b) a polyethylene glycol (PEG) ester of a fatty acid.
4. The oral pharmaceutical composition of claim 1 , wherein said oil-based liquid formulation, further comprises a self-emulsifying component.
5. The oral pharmaceutical composition of claim 1 , wherein said insulin is present in an amount between 8-12 mg inclusive for an adult patient or a corresponding amount per body weight for a pediatric patient.
6. The oral pharmaceutical composition of claim 5 , wherein said exenatide is present in an amount between 100-300 micrograms inclusive for an adult patient or a corresponding amount per body weight for a pediatric patient.
7. The oral pharmaceutical composition of claim 1 , wherein said chelator is EDTA.
8. The oral pharmaceutical composition of claim 1 , wherein said oil is fish oil.
9. The oral pharmaceutical composition of claim 1 , wherein said oil-based liquid formulation is water-free.
10. The oral pharmaceutical composition of claim 1 , wherein said composition is a pH-sensitive capsule.
11. The oral pharmaceutical composition of claim 5 , wherein said insulin is present in an amount of about 8 mg.
12. A method for treating a human with Type 2 diabetes mellitus, said method comprising the steps of selecting a human diagnosed with Type 2 diabetes mellitus, and administering to said human the oral pharmaceutical composition of claim 1 , thereby treating a human with Type 2 diabetes mellitus.
13. A method for treating a non-human animal with diabetes mellitus, said method comprising the step of administering to said non-human animal the oral pharmaceutical composition of claim 1 , thereby treating a non-human animal with diabetes mellitus.
14. A method for reducing postprandial glucose excursion in a human with Type 2 diabetes mellitus, said method comprising the steps of selecting a human diagnosed with Type 2 diabetes mellitus, and administering to said human the oral pharmaceutical composition of claim 1 , thereby reducing postprandial glucose excursion in a human with Type 2 diabetes mellitus.
15. A method for reducing postprandial glucose excursion in a non-human animal with diabetes mellitus, said method comprising the step of administering to said non-human animal the oral pharmaceutical composition of claim 1 , thereby reducing postprandial glucose excursion in a non-human animal with diabetes mellitus.
16. The oral pharmaceutical composition of claim 6 , wherein said exenatide is present in an amount of about 300 micrograms.
17. The oral pharmaceutical composition of claim 16 , wherein said insulin is present in an amount of about 8 mg.
18. The oral pharmaceutical composition of claim 1 , wherein said insulin is human insulin.
19. A method for treating a human with an elevated fasting blood glucose level, said method comprising administering to said human the oral pharmaceutical composition of claim 1 .
20. A method for treating a non-human animal with an elevated fasting blood glucose level, said method comprising administering to said non-human animal the oral pharmaceutical composition of claim 1 .